UBS Group AG Increases Stock Position in Lexicon Pharmaceuticals, Inc. $LXRX

UBS Group AG boosted its stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 752.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,007,237 shares of the biopharmaceutical company’s stock after purchasing an additional 2,654,315 shares during the quarter. UBS Group AG owned about 0.83% of Lexicon Pharmaceuticals worth $3,458,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Hudson Bay Capital Management LP bought a new position in Lexicon Pharmaceuticals during the second quarter valued at approximately $26,000. Vermillion & White Wealth Management Group LLC grew its position in Lexicon Pharmaceuticals by 400.0% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 32,500 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 26,000 shares during the last quarter. XTX Topco Ltd grew its position in Lexicon Pharmaceuticals by 431.4% during the second quarter. XTX Topco Ltd now owns 66,276 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 53,805 shares during the last quarter. Bank of America Corp DE grew its position in Lexicon Pharmaceuticals by 80.1% during the third quarter. Bank of America Corp DE now owns 57,804 shares of the biopharmaceutical company’s stock valued at $78,000 after acquiring an additional 25,707 shares during the last quarter. Finally, Optiver Holding B.V. grew its position in Lexicon Pharmaceuticals by 2,400.6% during the third quarter. Optiver Holding B.V. now owns 75,893 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 72,858 shares during the last quarter. 74.70% of the stock is owned by hedge funds and other institutional investors.

Lexicon Pharmaceuticals Price Performance

Shares of NASDAQ LXRX opened at $2.16 on Monday. Lexicon Pharmaceuticals, Inc. has a one year low of $0.62 and a one year high of $2.53. The company has a debt-to-equity ratio of 0.24, a current ratio of 18.80 and a quick ratio of 18.77. The firm’s 50 day simple moving average is $1.80 and its two-hundred day simple moving average is $1.52. The stock has a market capitalization of $959.46 million, a P/E ratio of -30.85 and a beta of 0.97.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $0.00 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.04. Lexicon Pharmaceuticals had a negative net margin of 37.46% and a negative return on equity of 18.64%. The business had revenue of $21.10 million for the quarter, compared to analysts’ expectations of $9.79 million. As a group, analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.17 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on LXRX. Citigroup increased their price target on shares of Lexicon Pharmaceuticals from $2.30 to $3.10 and gave the company a “buy” rating in a research report on Monday, May 11th. HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Lexicon Pharmaceuticals in a research report on Monday, March 23rd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $4.55.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.